Granules India Limited

15%

Y-o-Y performance highlights Q3 FY23 Q3 FY22 Y-o-Y Gr% Y-o-Y performance Revenue 1,146 997 15% Growth driven by commercialisation efforts made in key geographies including US Value Added 554

48.4%

mercialisation efforts made in key geographies including US Value Added 554 465 Value Added % 48.4% 46.6% 19% Better VA% due to better product mix EBITDA EBITDA % PAT PAT % 231 174 20.2% 1

46.6%

isation efforts made in key geographies including US Value Added 554 465 Value Added % 48.4% 46.6% 19% Better VA% due to better product mix EBITDA EBITDA % PAT PAT % 231 174 20.2% 17.5% 1

19%

efforts made in key geographies including US Value Added 554 465 Value Added % 48.4% 46.6% 19% Better VA% due to better product mix EBITDA EBITDA % PAT PAT % 231 174 20.2% 17.5% 124 1

20.2%

% 48.4% 46.6% 19% Better VA% due to better product mix EBITDA EBITDA % PAT PAT % 231 174 20.2% 17.5% 124 101 10.8% 10.1% 33% 23% 3 Q3FY23: Q-o-Q performance highlights Q3 FY23 Q2 FY23

17.5%

% 46.6% 19% Better VA% due to better product mix EBITDA EBITDA % PAT PAT % 231 174 20.2% 17.5% 124 101 10.8% 10.1% 33% 23% 3 Q3FY23: Q-o-Q performance highlights Q3 FY23 Q2 FY23 Q-o-Q

10.8%

tter VA% due to better product mix EBITDA EBITDA % PAT PAT % 231 174 20.2% 17.5% 124 101 10.8% 10.1% 33% 23% 3 Q3FY23: Q-o-Q performance highlights Q3 FY23 Q2 FY23 Q-o-Q Gr% Q-o-Q perfo

10.1%

% due to better product mix EBITDA EBITDA % PAT PAT % 231 174 20.2% 17.5% 124 101 10.8% 10.1% 33% 23% 3 Q3FY23: Q-o-Q performance highlights Q3 FY23 Q2 FY23 Q-o-Q Gr% Q-o-Q performance

33%

o better product mix EBITDA EBITDA % PAT PAT % 231 174 20.2% 17.5% 124 101 10.8% 10.1% 33% 23% 3 Q3FY23: Q-o-Q performance highlights Q3 FY23 Q2 FY23 Q-o-Q Gr% Q-o-Q performance Flat

23%

ter product mix EBITDA EBITDA % PAT PAT % 231 174 20.2% 17.5% 124 101 10.8% 10.1% 33% 23% 3 Q3FY23: Q-o-Q performance highlights Q3 FY23 Q2 FY23 Q-o-Q Gr% Q-o-Q performance Flat Sale

0%

key geographies including US This has impacted the VA% and EBITDA% as well Revenue 1,146 1,151 0% Value Added 554 572 Value Added % 48.4% 49.7% EBITDA EBITDA % PAT PAT % 231 243 20.2%

49.7%

he VA% and EBITDA% as well Revenue 1,146 1,151 0% Value Added 554 572 Value Added % 48.4% 49.7% EBITDA EBITDA % PAT PAT % 231 243 20.2% 21.1% 124 145 10.8% 12.6% (3%) (5%) (14%) 4

Total GPI products include

1

Corporate address

1

Total GPI products include

CII – 8 PFOS – 4 Liquid Orals – 3 GPI IP USA 23 1 5 29 GIL IP USA Europe Canada South Africa UK 27 1 11 39 4 4 8 4 2 6 1 1 2 3 3 Total 59 2 26 87 ANDA/Dossier filed - Therapeutic area wise 24 19 Analgesics Central Nervous System Cardiovascular Anti-diabetics Mineral supplements Anti-Histamines Anti-gout Antitussives Other areas 9 8 5 4 3 3 12 8 5-year trajectory: Revenue and Profitability (In ₹ Mn) Revenue Value Added and VA % 37,649 32,375 33,164 25,986 22,792 16,918 18,463 18,813 57.0% 16,326 50.0% 49.2% 13,177 50.7% 7,955 47.0% 10,236 44.9% FY18 FY19 FY20 FY21 FY22 9M FY23 FY18 FY19 FY20 FY21 FY22 9M FY23 EBITDA & EBITDA Margin PAT & PAT Margin 8,552 26.4% 7,222 6,857 20.7% 19.2% 5,253 20.2% 5,495 17.0% 4,128 3,970 11.0% 12.0% 3,354 2,364 12.9% 10.4% 1,326 7.8% FY20 FY21 FY22 9M FY23 FY18 FY19 FY20 FY21 FY22 9M FY23 9 3,840 2,784 16.5% FY18 16.8% FY19 5-year trajectory: Market and Segment mix (In ₹ Mn) Higher revenue contribution coming from regulated market, 73% of total revenues F

Corporate address

Floor 2 Block 3 My Home Hub Madhapur Hyderabad 500081 CIN: L24110TG1991PLC012471 Voice: +91 40 69043600 www.granulesindia.com 532482 GRANULES GRAN:IN GRAN:NS